The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes is reviewed in the following study. At Dream Body Clinic we use mesenchymal stem cells administered at 300 million MSCs in an IV for the treatment of Type 2 Diabetes. Learn more about dream body clinic’s type 2 diabetes stem cell therapy here.
Bone fragility has emerged as a new complication of Type 2 Diabetes (T2D). The pathophysiological link between bone fragility and diabetes is not completely understood. Several mechanisms may influence bone homeostasis by impairing the function of osteoblasts, osteoclasts and osteocytes and/or changing the structural properties of the bone tissue. Notably, adipocytes and osteoblasts are derived from a common precursor, the mesenchymal stem cell (MSC), and the differentiation is modulated by several interacting pathways that may be disrupted in diabetes. Other organs and endocrine systems such as the gut, kidney, and cardiovascular and vitamin D systems are altered in diabetes and, therefore may also affect bone metabolism. As a result, fractures are an added burden in diabetes. However, while bone mineral density (BMD) is decreased in patients with Type diabetes (T2D), it is normal or even increased in patients. In this review, we describe the main factors that impair bone health in diabetic patients and their clinical impact.
